Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
32.47 ^USD	-1.58%		-8.74%	+50.88%

Apr. 19	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
Apr. 19	Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	MT

Aeglea BioTherapeutics : PEACE Phase 3 Topline Data Webcast

December 05, 2021 at 06:12 pm EST

December 6, 202108:00 AM ET

Add to Calendar

Add to Apple Calendar
Add to Google Calendar
Add to Microsoft Outlook
Add to iCalendar

Webcast

Remind me24 Hours 3 Days 7 Days

Email:

Please provide an email address.Please provide a valid email address.

Unauthorized recording or downloading of this event is not permitted.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Aeglea Bio Therapeutics Inc. published this content on 06 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 December 2021 23:11:03 UTC.

Latest news about Spyre Therapeutics, Inc.

Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	Apr. 19	MT
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	Mar. 26	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	Mar. 17	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	Mar. 01	MT
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics, Inc. Announces Board Changes	Feb. 05	CI
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	Dec. 26	CI
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	Dec. 20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	Dec. 18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	Dec. 11	MT
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	Dec. 08	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors	Dec. 06	CI
Spyre Therapeutics, Inc.(NasdaqCM:SYRE) added to NASDAQ Composite Index	Nov. 29	CI
Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE	Nov. 28	CI
Aeglea BioTherapeutics, Inc. will Change its Name to Spyre Therapeutics, Inc	Nov. 28	CI
Aeglea BioTherapeutics Changes Name to Spyre Therapeutics; CEO Appointed	Nov. 27	MT
Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer	Nov. 27	CI
Aeglea BioTherapeutics, Inc. Announces Executive Changes	Nov. 27	CI
Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index	Nov. 27	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

Chart Spyre Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Spyre Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.99 USD

Average target price

42 USD

Spread / Average Target

+27.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPYRE THERAPEUTICS, INC.	+50.88%	1.21B
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs